Massachusetts Eye and Ear Infirmary
Trial Pipeline
Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait
NCT06688578
The Glaucoma and Retinopathy Screening Study
NCT06882356
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
NCT06753916
ctDNA in Cutaneous Squamous Cell Carcinoma
NCT06875609
A Trial of Hydrus Microstent Versus Goniotomy
NCT06289491
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
NCT06744296
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
NCT06033703
Reminder-cue Scanning Training for Homonymous Visual Field Loss
NCT06136169
Improving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America's Population Mean Mapping Strategy
NCT06960616
Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
NCT05150106
Perceptual Consequences of Cochlear Implant Electrode-neuron Interfaces
NCT05867173
Dropless Pars Plana Vitrectomy Study
NCT05331664
Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
NCT05150093
Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
NCT05317390
Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
NCT05216770
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
NCT04225611
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
NCT04735263
Feasibility Tests for Various Prism Configurations for Visual Field Loss
NCT04424979
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
NCT04440280
Brain Networks in Dystonia
NCT03042962
Simulated Walking With Multiplexing Prism for Field Expansion in Monocular Vision
NCT06024668
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
NCT06971276
Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia
NCT04827147
Doxycycline in Cutaneous Schwannoma (NF2)
NCT05521048
Feasibility Test of Virtual Reality Obstacle Detection for Low Vision Walking
NCT05141604
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
NCT04321954
Study of Aspirin in Patients With Vestibular Schwannoma
NCT03079999
Anti-VEGF Therapy for Acute Thyroid Eye Disease
NCT04311606
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
NCT06730412
Clinical Trial to Improve the Magnetic Levator Prosthesis
NCT03818204
Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
NCT04057053
Mobile Medical Application for Cost-effective Strabismus Screening
NCT03450980
Perioperative Complications of Deep Extubation in Adults
NCT04557683
Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
NCT02592330
Computer-Based Auditory Rehabilitation
NCT02147847
Randomized Controlled Trial of Voice on Children With Vocal Nodules
NCT01255735
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
NCT00824824
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
NCT00765921
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 34 |
| Phase 4 | 1 |
What the Pipeline for Massachusetts Eye and Ear Infirmary Shows
According to the ClinicalTrials.gov registry, Massachusetts Eye and Ear Infirmary is linked to 94 US clinical trials across every stage of research activity. Of those, 76 studies are currently recruiting — about 81% of the sponsor's indexed portfolio — and 11 are already marked complete, representing roughly 12% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Massachusetts Eye and Ear Infirmary reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 41 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Massachusetts Eye and Ear Infirmary is Spasmodic Dysphonia with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.